WITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT

Size: px

Start display at page:

Download "WITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT"

Garey Murphy
6 years ago
Views:

1 WITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT

2 Pharmaceutical IP Policy Issues Economics - Business Model IP TPP Global Challenges Access

PRE-DISCOVERY Valuable But Vulnerable: Limitless Possibilities, Growing Challenges IND SUBMITTED NDA SUBMITTED Developing a new medicine is lengthy, risky, and costly.

3 PRE-DISCOVERY Valuable But Vulnerable: Limitless Possibilities, Growing Challenges IND SUBMITTED NDA SUBMITTED Developing a new medicine is lengthy, risky, and costly. New drug development takes an average of years, and costs approx. US $1.3 billion. Drug Discovery Preclinical Clinical Trials FDA Review Scale-Up to Mfg. Post-Marketing Surveillance ~ 5,000 10, COMPOUNDS ONE FDA- APPROVED DRUG PHASE 1 PHASE 2 PHASE 3 NUMBER OF VOLUNTEERS ,000 5, YEARS 6 7 YEARS YEARS INDEFINITE Sources: Drug Discovery and Development: Understanding the R&D Process, 3

Number of Alzheimer s Drugs No Longer Under Development Setbacks in Alzheimer s Disease Research Provide Stepping Stones for Future Innovation Since 1998, 123

These setbacks highlight the complexity of the R&D process. Though disappointing, they provide important knowledge to fuel future research.

4 Number of Alzheimer s Drugs No Longer Under Development Setbacks in Alzheimer s Disease Research Provide Stepping Stones for Future Innovation Since 1998, 123 medicines in development for the treatment of Alzheimer s disease have not made it through clinical trials, with only 4 gaining FDA approval. These setbacks highlight the complexity of the R&D process. Though disappointing, they provide important knowledge to fuel future research. Unsuccessful Alzheimer s Drugs in Development, Source: PhRMA 22 2 Research and Development 35

5 Illustrative Pharmaceutical Lifecycle New pharmaceutical medicines face competition after a relatively short period on the market. FDA Approval Most brand drugs face competition from other brands Generics Enter Market DRUG DEVELOPMENT BRAND DRUG LIFESPAN GENERICS Average time to develop a new medicine = at least 10 yrs Average time on market before generic entry = 12.5* yrs *For brand medicines with more than $250 million in annual sales in 2008 dollars, which account for 92% of sales of the brand medicines analyzed Sources: PhRMA 1 ; Grabowski H, et al. 2 ; Tufts CSDD 3 3 Market Dynamics 46

6 Median Number of Years Increasing Competition Within Therapeutic Categories The time a medicine is the only drug available in its pharmacologic class declined from a median of more than 10 years in the 1970s to close to 2 years in the 2000s. Time Between Approval of First and Second Medicines in a Pharmacologic Class Half of second medicines in a class were approved within 2.3 years of the first medicine s approval. One quarter were approved within just 4 months s Year of Approval of First in Class Medicine Source: Tufts CSDD 4 3 Market Dynamics 47

7 2005 Dollars, in Billions Few Approved Medicines Are Commercially Successful Ongoing investment in R&D depends on the commercial success of a few products that must make up for all the rest, including those that never reach the market. $55 $50 $45 $40 $35 $30 $25 $20 $15 $10 $5 Present Value of Lifetime Sales of Medicines Introduced Just 2 in 10 Approved Medicines Produce Revenues That Exceed Average R&D Costs 9 $0 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% Medicines by Lifetime Sales Percentile A medicine is defined as a novel active substance (ie, a molecular or biologic entity or combination product in which at least one element had not been previously approved by the FDA). Sales are global sales net of rebates and discounts. Sources: Berndt ER, et al. 8 ; Vernon JA, et al. 9 3 Market Dynamics 50

8 Potential First in Class Medicines in the Pipeline An average of 70% of drugs across the pipeline are potential first in class medicines. Percentage of Projects in Development That Are Potentially First in Class Medicines in Selected Therapeutic Areas, 2011 Neurology Cardiovascular Cancer Psychiatry 84% 81% 80% 79% Immunology Diabetes HIV/AIDS 71% 69% 72% Infections 57% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Source: Analysis Group 2 2 Research and Development 23

9 Biopharmaceutical Companies Do the Vast Majority of Research to Translate Basic Science Into New Medicines While basic science is often initiated in government and academia, it is biopharmaceutical firms that provide the necessary critical mass, expertise, and experience needed to develop new medicines PhRMA Member Companies Biopharmaceutical R&D Investment: $58.8 Billion (est.) 11,13 Management & Administration Applied Research Applied Research Basic Research Basic Research 2015 TOTAL NIH Budget: $30.3 Billion 11,14 In addition to biopharmaceutical R&D, the NIH budget includes funding in support of medical devices, diagnostics, prevention, training, and other activities. Sources: Tufts CSDD 12 ; PhRMA 13 ; NIH 14 2 Research and Development 30

Expenditures (in Billions of Dollars) PhRMA Member Company R&D Investment The pharmaceutical industry is one of the most research intensive industries in the United States.

10 Expenditures (in Billions of Dollars) PhRMA Member Company R&D Investment The pharmaceutical industry is one of the most research intensive industries in the United States. Pharmaceutical firms invest as much as five times more in research and development, relative to their sales, than the average U.S. manufacturing firm. Congressional Budget Office (CBO) 19 PhRMA Member Company R&D Expenditures, $60 $58.8* $50 $50.7 $40 $39.9 $30 $26.0 $20 $10 $15.2 $0 *Estimated fiscal year 2015 Sources: CBO 19 ; PhRMA 20 2 Research and Development 33

11 TPP IP PERSPECTIVES It is the opinion of ITAC-15 1 that to a reasonable extent and with consideration of the broader impact of this agreement, the TPP promotes the economic interests of the United States and advances the overall and principal negotiating objectives with respect to intellectual property set forth in section 102 of the Bipartisan Congressional Trade Priorities and Accountability Act of ITAC Members representing BIO and PhRMA and those representing companies that are members of PhRMA or BIO reserve their position on this statement. Property.pdf.

12 Extending Data Protection - Budget Impact Canada 2006 RDP went from 0 to 8 years 2006 medicines spend = 17.2% total health spend 2011 medicines spend = 16.6% total health spend

13 ILLUSTATIVE GLOBAL CHALLENGES BRAZIL ANVISA CHINA Regulatory Data Protection CANADA Utility requirement INDIA New formulations and other follow-on innovations

14 COMPULSORY LICENSING - COLOMBIA Glivec introduced into Colombia at government determined price 100% Access 2 generic versions marketed in Colombia March 4, 2016 Minister of Health recommended complusory license September 2016 Government said it would impose severe price reduction

15 CONTENTION: Ever-greening Patent protection on original product extended by grant of follow-on patents on new formulations - prevents generics from commercializing the original product, even after expiration of the original product patent. REALITY: The secondary patent protects only the improved product, not the original product. Generic applicants are free to market the original product if its patent is expired. Copyright 2012 Eli Lilly and Company 15

16 Ever-greening is a False Premise: A Real-World Example PROZAC, a first-in-class therapy for major depressive disorder, launched in 1987 Daily dosage regimen, generally 20mg/day Patent protection expired August 2001 PROZAC Weekly TM approved February 2001 Separate patent protection for weekly dosing regimen Launched only months before expiration of PROZAC compound patent Generic applicants were free to launch Prozac for daily use after expiration of the compound patent Patients & Doctors decide whether the secondary patent has value Copyright 2012 Eli Lilly and Company 16

17 R&D ON NEGLECTED DISEASES OF DEVELOPING WORLD THREE LARGEST FUNDING SOURCES IN ORDER: UNITED STATES (71% OF GOVERNMENT CONTRIBUTIONS) GATES FOUNDATION ( 78% OF PHILANTHROPIC) PHARMACEUTICAL INDUSTRY (68% OF PRIVATE SECTOR) LARGER THAN EC AND EU MEMBER STATE CONTRIBUTIONS CHEMICAL LIBRARY CONTRIBUTIONS VALUED AT G-FINDER REPORT

18 Committed to Sustainable Access Solutions Support over 340 initiatives with more than 600 partners to improve health $94.8 billion contributed since 2000 towards achieving UN Millennium Development Goals on Health Product donations and wide array of capacity building interventions to strengthen local health care institutions and improve access Source: Norris, Jeremiah et. al., The Pharmaceutical Industry s Contributions to the United Nations Millennium Development Goals, Hudson Institute Center for Science in Public Policy Economic Policy/Briefing Paper, 16 (2013). Available at: 18

19 Barriers to Access Insufficient infrastructure - lack of: trained health care workers; health care systems; transportation Inadequate Government investment Significant mark ups in distribution chain High government taxes and tariffs Sources: See, e.g., Wilsdon, Tim et. al., Evidence on Access to Essential Medicines for the Treatment of HIV/AIDS (2011). 19

20 Eliminating IP Does not Solve Access Problems for the Poor India - Between 1970 and 2005 no patents on medicines large generic industry developed WHO - Between 2000 and 2007 in India Access to medicines among worst in world 30.00% 25.00% 20.00% 15.00% 10.00% 5.00% 0.00% 17.90% Access to Essential Medicines 20% 20.50% 23.40% Ghana Uganda India United Rep. of Tanzania Source: Health workforce, infrastructure, essential medicines, World Health Statistics 2009 WORLD HEALTH ORGANIZATION % Nigeria Median Percentage of Citizens with Access to Essential Medicines 20

21 THANK YOU

Access, Affordability and Innovation Focus on High Cost Medicines: Facts and Potential Options

Access, Affordability and Innovation Focus on High Cost Medicines: Facts and Potential Options Ashoke Bhattacharjya, PhD Robert E Campbell Pharmaceutical Seminar Rutgers Business School Feb 15, 2017 1